Literature DB >> 15558842

Mild phenotypes in a series of patients with Opitz GBBB syndrome with MID1 mutations.

Joyce So1, Vanessa Suckow, Zofia Kijas, Vera Kalscheuer, Bettina Moser, Jennifer Winter, Marieke Baars, Helen Firth, Peter Lunt, Ben Hamel, Peter Meinecke, Claude Moraine, Sylvie Odent, Albert Schinzel, J J van der Smagt, Koen Devriendt, Beate Albrecht, Gabriele Gillessen-Kaesbach, Ineke van der Burgt, Fred Petrij, Laurence Faivre, Julie McGaughran, Fiona McKenzie, John M Opitz, Timothy Cox, Susann Schweiger.   

Abstract

Opitz syndrome (OS; MIM 145410 and MIM 300000) is a congenital midline malformation syndrome characterized by hypertelorism, hypospadias, cleft lip/palate, laryngotracheoesophageal (LTE) abnormalities, imperforate anus, developmental delay, and cardiac defects. The X-linked form (XLOS) is caused by mutations in the MID1 gene, which encodes a microtubule-associated RBCC protein. In this study, phenotypic manifestations of patients with and without MID1 mutations were compared to determine genotype-phenotype correlations. We detected 10 novel mutations, 5 in familial cases, 2 in sporadic cases, and 3 in families for whom it was not clear if they were familial or sporadic. The genotype and phenotype was compared for these 10 families, clinically diagnosed OS patients found not to have MID1 mutations, and 4 families in whom we have previously reported MID1 mutations. This combined data set includes clinical and mutation data on 70 patients. The XLOS patients with MID1 mutations were less severely affected than patients with MID1 mutations reported in previous studies, particularly in functionally significant neurologic, LTE, anal, and cardiac abnormalities. Minor anomalies were more prevalent in patients with MID1 mutations compared to those without mutations in this study. Female MID1 mutation carriers had milder phenotypes compared to male MID1 mutation carriers, with the most common manifestation being hypertelorism in both sexes. Most of the anomalies found in the patients of the present study do not correlate with the MID1 mutation type, with the possible exception of LTE malformations. This study demonstrates the wide spectrum of severity and manifestations of OS. It also shows that XLOS patients with MID1 mutations may be less severely affected than indicated in prior reports. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15558842     DOI: 10.1002/ajmg.a.30407

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  15 in total

1.  Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1 is a sequence-dependent regulator of translation efficiency controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1).

Authors:  Beatriz Aranda-Orgillés; Désirée Rutschow; Raphael Zeller; Antonios I Karagiannidis; Andrea Köhler; Changwei Chen; Timothy Wilson; Sven Krause; Stefan Roepcke; David Lilley; Rainer Schneider; Susann Schweiger
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

2.  A mutation of beta -actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia.

Authors:  Vincent Procaccio; Gloria Salazar; Shoichiro Ono; Melanie L Styers; Marla Gearing; Antonio Davila; Richard Jimenez; Jorge Juncos; Claire-Anne Gutekunst; Germana Meroni; Bianca Fontanella; Estelle Sontag; Jean Marie Sontag; Victor Faundez; Bruce H Wainer
Journal:  Am J Hum Genet       Date:  2006-04-21       Impact factor: 11.025

3.  Mutations in SPECC1L, encoding sperm antigen with calponin homology and coiled-coil domains 1-like, are found in some cases of autosomal dominant Opitz G/BBB syndrome.

Authors:  Paul Kruszka; Dong Li; Margaret H Harr; Nathan R Wilson; Daniel Swarr; Elizabeth M McCormick; Rosetta M Chiavacci; Mindy Li; Ariel F Martinez; Rachel A Hart; Donna M McDonald-McGinn; Matthew A Deardorff; Marni J Falk; Judith E Allanson; Cindy Hudson; John P Johnson; Irfan Saadi; Hakon Hakonarson; Maximilian Muenke; Elaine H Zackai
Journal:  J Med Genet       Date:  2014-11-20       Impact factor: 6.318

4.  H-type tracheoesophageal fistula with type III laryngotracheoesophageal cleft.

Authors:  Brice Antao; Giampiero Soccorso; Neil Bateman; Rang Shawis
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-06-09       Impact factor: 2.503

5.  Two Novel Pathogenic MID1 Variants and Genotype-Phenotype Correlation Reanalysis in X-Linked Opitz G/BBB Syndrome.

Authors:  Nuno Maia; Maria J Nabais Sá; Nataliya Tkachenko; Gabriela Soares; Isabel Marques; Bárbara Rodrigues; Ana M Fortuna; Rosário Santos; Arjan P M de Brouwer; Paula Jorge
Journal:  Mol Syndromol       Date:  2017-08-29

6.  X-linked Opitz G/BBB syndrome: identification of a novel mutation and prenatal diagnosis in a Korean family.

Authors:  Hyun-Jung Cho; Mee-yong Shin; Kang-Mo Ahn; Sang Il Lee; Hee-Jin Kim; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

7.  The Challenge of Prenatal Diagnostic Work-Up of Maternally Inherited X-Linked Opitz G/BBB: Case Report and Literature Review.

Authors:  Marialuigia Spinelli; Carmine Sica; Bruno Dallapiccola; Antonio Novelli; Letizia Di Meglio; Pasquale Martinelli
Journal:  Case Rep Obstet Gynecol       Date:  2015-05-04

8.  Characterization With Gene Mutations in Han Chinese Patients With Hypospadias and Function Analysis of a Novel AR Genevariant.

Authors:  Lifen Chen; Junqi Wang; Wenli Lu; Yuan Xiao; Jihong Ni; Wei Wang; Xiaoyu Ma; Zhiya Dong
Journal:  Front Genet       Date:  2021-06-30       Impact factor: 4.599

9.  Active transport of the ubiquitin ligase MID1 along the microtubules is regulated by protein phosphatase 2A.

Authors:  Beatriz Aranda-Orgillés; Johanna Aigner; Melanie Kunath; Rudi Lurz; Rainer Schneider; Susann Schweiger
Journal:  PLoS One       Date:  2008-10-24       Impact factor: 3.240

10.  MID1 catalyzes the ubiquitination of protein phosphatase 2A and mutations within its Bbox1 domain disrupt polyubiquitination of alpha4 but not of PP2Ac.

Authors:  Haijuan Du; Kuanlin Wu; Alma Didoronkute; Marcus V A Levy; Nimish Todi; Anna Shchelokova; Michael A Massiah
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.